Lack­lus­ter da­ta on Alzheimer's drugs lead to end of Roche-AC Im­mune part­ner­ship

Roche and Genen­tech have end­ed a near­ly two-decade Alzheimer’s dis­ease part­ner­ship with Swiss biotech AC Im­mune af­ter nu­mer­ous set­backs and cloudy da­ta.

The col­lab­o­ra­tion in­volved work­ing to­geth­er on two Alzheimer’s pro­grams, crenezum­ab and se­morinemab, that will both be re­turned to AC Im­mune, the biotech said in a press re­lease Mon­day. In an emailed state­ment to End­points News, a Roche spokesper­son said in no un­cer­tain terms that da­ta drove the de­ci­sion to end the team-up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER